E-LIB Suche - Ergebnisse für: Zelenetz, A.D.

1

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE ..:

Cheah, C. Y. ; Shah, N. N. ; Jurczak, W....
Hematological Oncology. 41 (2023) S2 - p. 153-156 , 2023

Link: https://doi.org/10.1002/..

2

Genetic Alterations in Follicular Lymphoma Predict Response..:

Wijetunga, N. A. ; Lebow, E. ; Chan, A....
Hematological Oncology. 41 (2023) S2 - p. 291-292 , 2023

Link: https://doi.org/10.1002/..

3

Treatment outcomes of Limited Stage Grade 3A Follicular Lym..:

Sarkar, R. R. ; Lee, J. ; Zhang, Z....
Hematological Oncology. 41 (2023) S2 - p. 378-380 , 2023

Link: https://doi.org/10.1002/..

4

PET‐Adapted Therapy with Nivolumab plus Adriamycin, Vinblas..:

Moskowitz, A. ; Savage, K. ; Feldman, T....
Hematological Oncology. 41 (2023) S2 - p. 351-353 , 2023

Link: https://doi.org/10.1002/..

5

S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INT..:

Zelenetz, A. ; Jurczak, W. ; Ribrag, V....
HemaSphere. 6 (2022) - p. 109-110 , 2022

Link: https://doi.org/10.1097/..

6

P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT ..:

Soumerai, J. D. ; Jagadeesh, D. ; Salman, H....
HemaSphere. 6 (2022) - p. 1004-1005 , 2022

Link: https://doi.org/10.1097/..

7

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglo..:

Kumar, Anita ; Bantilan, K.S. ; Jacob, A.P....
Clinical Lymphoma Myeloma and Leukemia. 21 (2021) 4 - p. 230-237.e12 , 2021

Link: https://doi.org/10.1016/..

8

CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAG..:

Sha, F. ; Okwali, M. ; Alperovich, A....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS)..:

Pagel, J. ; Reddy, N. ; Jagadeesh, D....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPS..:

Farina, K. A ; Drill, E ; Buie, L. W...
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

11

PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VE..:

Kumar, A. ; Batlevi, C. ; Drullinsky, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

12

CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LA..:

Bobillo, S. ; Joffe, E. ; Lavery, J....
Hematological Oncology. 37 (2019) S2 - p. 251-252 , 2019

Link: https://doi.org/10.1002/..

13

INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORM..:

Rajeeve, S. ; Bobillo, S.V. ; Zelenetz, A.D....
Hematological Oncology. 37 (2019) S2 - p. 264-266 , 2019

Link: https://doi.org/10.1002/..

14

PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WI..:

Mato, A.R. ; Svoboda, J. ; Luning Prak, E.T....
Hematological Oncology. 37 (2019) S2 - p. 119-120 , 2019

Link: https://doi.org/10.1002/..

15

THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTO..:

Zelenetz, A.D. ; Jagadeesh, D. ; Kenkre, V.P....
Hematological Oncology. 37 (2019) S2 - p. 176-177 , 2019

Link: https://doi.org/10.1002/..